The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

SIMPLE SUMMARY: Although taxane-trastuzumab-pertuzumab combinations in the first-line treatment setting significantly improved clinical outcomes in patients with Human Epidermal growth factor Receptor 2 positive (HER2+) advanced breast cancer (aBC), their clinical efficacy is highly heterogeneous, a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Ligorio, Francesca, Fucà, Giovanni, Zattarin, Emma, Lobefaro, Riccardo, Zambelli, Luca, Leporati, Rita, Rea, Carmen, Mariani, Gabriella, Bianchi, Giulia V., Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073809/
https://ncbi.nlm.nih.gov/pubmed/33921727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13081964
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares